ARGILIFE

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT ARGYLIFE (ARGILIFE)

Composition:

Active substance: L-arginine L-aspartate;

1 ml of solution contains L-arginine L-aspartate – 200 mg;

Excipients: sorbitol (E 420), sodium saccharin (E 954), methylparahydroxybenzoate (E 218), propylparahydroxybenzoate (E 216), food flavoring "Caramel", purified water.

Pharmaceutical form. Oral solution.

Main physicochemical properties: slightly yellowish liquid with a caramel odor.

Pharmacotherapeutic group. Other cardiac preparations. Amino acids.

ATC code C01E.

Pharmacological Properties

Pharmacodynamics

The medicinal product Argilife exerts anti-hypoxic, cytoprotective, antioxidant, detoxifying, and membrane-stabilizing effects. It plays an important role in ammonia neutralization and stimulates its excretion from the body, enhancing the liver's detoxification function. It exerts hepatoprotective action and positively influences energy supply processes in hepatocytes.

As a nitric oxide donor, Argilife participates in the body's energy supply processes, reduces activation and adhesion of leukocytes and platelets to the vascular endothelium, thus preventing the formation and progression of atherosclerotic plaques, and is involved in fibrinogenolysis and spermatogenesis processes.

The medicinal product exerts a moderate anabolic effect, stimulates thymus gland activity, promotes insulin synthesis, regulates blood glucose levels during physical exertion, and contributes to correction of acid-base balance.

Pharmacokinetics

Not studied.

Clinical characteristics.

Indications.

Used in the complex therapy of atherosclerosis of the heart and cerebral vessels, arterial hypertension, peripheral vascular atherosclerosis; chronic heart failure; hypercholesterolemia; chronic obstructive pulmonary diseases, pulmonary hypertension; asthenic conditions.

Contraindications.

Hypersensitivity, severe renal function impairment. Myocardial infarction (including history of).

Interaction with other medicinal products and other forms of interaction.

When using arginine aspartate, it should be taken into account that concomitant use of aminophylline with arginine may be accompanied by an increase in blood insulin levels, and concomitant use of spironolactone with arginine may lead to increased blood potassium levels.

Arginine is incompatible with thiopental.

Special precautions for use

The medicinal product should be used with caution in patients with electrolyte imbalance and kidney diseases. During treatment, a balanced regimen of sleep and rest should be maintained, and consumption of alcohol, nicotine, and psychostimulants should be avoided. If symptoms of asthenia worsen during administration of the drug, treatment should be discontinued.

The drug should be used with caution in patients with angina pectoris.

The medicinal product contains sorbitol (E 420); therefore, if intolerance to certain sugars is known, consult a physician before taking this medicinal product.

The product contains auxiliary substances such as methylparahydroxybenzoate (E 218) and propylparahydroxybenzoate (E 216), which may cause allergic reactions (possibly delayed).

This medicinal product contains less than 0.015 mmol (0.34 mg) of sodium per dose (5 ml), i.e., it is practically sodium-free.

Use during pregnancy or breastfeeding

The drug crosses the placental barrier; therefore, during pregnancy it should be used only when the expected benefit to the mother outweighs the potential risk to the fetus.

There are no data available on the use of the drug during breastfeeding.

Ability to influence reaction rate when driving or operating machinery

No effect.

Method of Administration and Dosage

Administer orally, take during meals.
For adults:

• In case of atherosclerosis of cardiac and cerebral vessels, peripheral vascular atherosclerosis – 5 ml (1 measuring spoon (5 ml) – 1 g of arginine aspartate) 3–8 times daily.
• In hypercholesterolemia, arterial hypertension – 5 ml 3–6 times daily.
• In chronic obstructive pulmonary diseases, pulmonary hypertension – 5 ml 3–6 times daily.
• In asthenic conditions – 5 ml 4–8 times daily.

Maximum daily dose – 8 g.
Duration of treatment course – 8–15 days; if necessary, the course may be repeated.

Children

Not recommended for patients under 18 years of age.

Overdose

Symptoms: hypersensitivity reactions, hypoglycemic conditions.

Treatment: If these symptoms occur, discontinue the drug immediately. Gastric lavage and administration of sorbents are indicated. No antidote is available. Symptomatic therapy should be provided.

Side effects.

Musculoskeletal system: joint pain.

Gastrointestinal tract: rarely – mild discomfort in the stomach and intestine, nausea immediately after administration of the medicinal product, which resolve spontaneously.

Immune system: hypersensitivity reactions, including bronchospasm.

Laboratory findings: hyperkalemia.

Shelf life. 1 year.

Shelf life after opening the bottle – 14 days.

Storage conditions.

Store in the original packaging at a temperature not exceeding 25 °C. Keep out of reach of children. Do not freeze.

Packaging.

200 ml in a bottle; 1 bottle with a measuring spoon in a carton.

Availability.

Over-the-counter.

Manufacturer.

JSC "Halychpharm".

Manufacturer's address and place of business.

6/8 Opryshkivska Street, Lviv, 79024, Ukraine.